Ebastine in perennial allergic rhinitis.
Ebastine in perennial allergic rhinitis.
复制标题
依巴斯汀治疗常年性过敏性鼻炎。
DOI：
--
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Zayas Sanza Jm
中科院分区：
文献类型：
--
作者：
C. PicadoVallés;A. CadahiaGarcía;A. CisteróBahima;L. CanoCantudo;A. SanzAmaro;Zayas Sanza Jm
：在一项多中心、随机、双盲试验中，对 151 名患者口服依巴斯汀（10 毫克，每日一次，持续 7 天）与安慰剂治疗活动性常年性过敏性鼻炎进行了比较。依巴斯汀治疗显着降低了与常年性鼻炎相关的大多数症状的发生率和严重程度。两个治疗组的耐受性相似。在接受活性药物治疗的患者中，嗜睡和口干的发生率并不更高。
: Oral ebastine, 10 mg once daily for seven days, and placebo were compared as treatment for active perennial allergic rhinitis in 151 patients in a multicenter, randomized, double-blind trial. Ebastine treatment produced a significant reduction in the incidence and severity of most symptoms associated with perennial rhinitis. Tolerability was similar in the two treatment groups. The incidences of drowsiness and dry mouth were not more frequent in the patients treated with the active drug.